AV Favipiravir
(Unterschied zwischen Versionen)
Ossip Groth (Diskussion | Beiträge)
(Die Seite wurde neu angelegt: „ {{tp|p=32401463|t=2006. Favipiravir|pdf=|usr=007}} {{tp|p=32346491|t=ä. Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study |pd…“)
Zum nächsten Versionsunterschied →
(Die Seite wurde neu angelegt: „ {{tp|p=32401463|t=2006. Favipiravir|pdf=|usr=007}} {{tp|p=32346491|t=ä. Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study |pd…“)
Zum nächsten Versionsunterschied →
Version vom 27. Juni 2020, 21:01 Uhr
32401463 2006. Favipiravir
32346491 ä. Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study
32246834 2020. Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019-nCoV Infection
32350860 2020. Dose Rationale for Favipiravir Use in Patients Infected With SARS-CoV-2
32360327 ä. Potential repurposing of Favipiravir in COVID-19 outbreak based on current evidence
32475019 2020. Pharmacokinetics of Favipiravir in Critically Ill Patients with COVID-19.
32417899 2020. Favipiravir, an antiviral for COVID-19?
